Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
Invivyd and the SPEAR Study Group initiated FLINTLOCK, a Phase 2 randomized, placebo-controlled trial of high-dose monoclonal antibody VYD2311 in adults with Long COVID or Post-Vaccination Syndrome. The trial enrolls approximately 130 participants, testing an IV loading dose followed by intramuscular injections at days 30 and 60 at a total dose targeted at 10x the prophylactic dose, with initial data expected in mid-2027.
Key figures
- Drug Name
- VYD2311
- Phase Of Trial
- Phase 2
- Liberty enrollment
- 210
- Initial data timing
- mid-2027
- Flintlock enrollment
- 130
- Declaration enrollment
- 2400
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.